Table I.
Demographic and clinical characteristics of the study population
| Chemo group (n = 19) | Control group (n = 15) | |
|---|---|---|
| Age | 56.3 (5.5) | 58.2 (5.8) |
| Estimated IQ (NART) | 101.1 (17.9) | 100.7 (17.3) |
| Years since surgery | 9.9 (0.5)* | 9.2 (0.5) |
| Years since chemotherapy | 9.5 (0.8) | NA |
| EORTC QLQ‐C30 | ||
| Global quality of life | 82.0 (12.1) | 81.1 (16.2) |
| Physical Functioning | 83.5 (12.2) | 88.4 (11.7) |
| Fatigue | 25.7 (14.4) | 23.0 (19.4) |
| HSCL‐25 total score | 11.30 (6.4) | 14.84 (16.3) |
| Cognitive complaints | ||
| Concentration, n (%) | 8 (42.1%) | 6 (40%) |
| Memory, n (%) | 11 (57.9%)* | 3 (20%) |
| Thinking, n (%) | 0 | 1 (6.7%) |
| Language, n (%) | 3 (15.8%) | 6 (40%) |
| Cognitive impairment, number of tests (%) | 1.71 (10.7%)* | 0.83 (5.2%) |
Abbreviations: NART = Dutch version of the National Adult Reading Test; EORTC QLQ‐C30 = European Organization for Research and Treatment of Cancer health‐related Quality‐of‐Life Questionnaire: scores range from 0 to 100; HSCL‐25 = Hopkins Symptom Checklist‐25: scores range from 0 to 100, higher score indicates higher levels of anxiety and depression; Cognitive complaints = number (and percentage) of subjects reporting cognitive complaints in telephone interview; Cognitive impairment = number (and percentage) of tests that subjects were impaired on (see text for details); NA = not applicable.
*
P < 0.05.